SGLT2 inhibitor dapagliflozin reduces proximal tubular cell damage biomarkers in patients with acute heart failure

SGLT2 inhibitor dapagliflozin reduces proximal tubular cell damage biomarkers in patients with acute heart failure

Saved in:

Bibliographic Details
Main Authors:	Pongsathorn Gojaseni, Jananya Wattanakul, Anan Chuasuwan, Anutra Chittinandana
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Renal Failure
Online Access:	https://www.tandfonline.com/doi/10.1080/0886022X.2024.2373275
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01)

Nanocarrier-encapsulated SGLT-2 inhibitor (dapagliflozin) protects against diabetic cardiomyopathy by reducing myocardial fibrosis
by: CY Li, et al.
Published: (2025-04-01)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024-11-01)

Coexposure to microplastic and Bisphenol A exhacerbates damage to human kidney proximal tubular cells
by: Daniela Verzola, et al.
Published: (2024-10-01)

Dynamic regulation of proximal tubular autophagy from injury to repair after ischemic kidney damage
by: Yuhong Gong, et al.
Published: (2024-12-01)

Risk factors associated with SGLT2 inhibitor discontinuation in diabetic patients with heart failure.
by: Minkwan Kim, et al.
Published: (2024-01-01)

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-02-01)

The The Impact of Dapagliflozin on Aldosterone Hormone in Rats with Heart Failure
by: Skala Mamand Jawhar, et al.
Published: (2023-09-01)

Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?
by: Massimo Mapelli, et al.
Published: (2025-03-01)

SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
by: Anna Murasheva, et al.
Published: (2024-12-01)

Clinical implications of proximal tubular multicilia in glomerular diseases
by: Bohye Kim, et al.
Published: (2025-02-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism
by: Brett W. Sperry, MD, et al.
Published: (2025-08-01)

Effects of dapagliflozin on podocyte damage and oxidative stress in patients with diabetic nephropathy
by: Yajing Shi, et al.
Published: (2025-08-01)

Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus
by: A. N. Payudis, et al.
Published: (2022-10-01)

Cardio–Renal and Systemic Effects of SGLT2i Dapagliflozin on Short-Term Anthracycline and HER-2-Blocking Agent Therapy-Induced Cardiotoxicity
by: Vincenzo Quagliariello, et al.
Published: (2025-05-01)

Author Correction: SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-04-01)

Role of SGLT2 inhibitors in the treatment of visceral obesity
by: M. A. Druzhilov, et al.
Published: (2021-02-01)

Osteomyelitis Pubis After Initiation of an SGLT2 Inhibitor
by: Adriana Nadeau, et al.
Published: (2022-10-01)

The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis
by: Chung-Shu Lee, et al.
Published: (2025-05-01)

Advances in the mechanism of action of SGLT2 inhibitors on the kidney
by: JI Ying, et al.
Published: (2020-01-01)

A study on the pharmacovigilance of various SGLT-2 inhibitors
by: Yanwen Dong, et al.
Published: (2025-01-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Renal Tubular Epithelial Cells as Marker of Tubular Damage in Acute Kidney Disease
by: Matthijs Oyaert, et al.
Published: (2025-08-01)

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper
by: João Pedro Ferreira, et al.
Published: (2025-08-01)

Cost-effectiveness of dapagliflozin for the treatment of heart failure: a systematic review
by: Zehui Jiang, et al.
Published: (2025-05-01)

Effects of SGLT2 inhibitors on cognitive impairment in elderly inpatients with heart failure with reduced ejection fraction: a prospective cohort study
by: Jiaying Li, et al.
Published: (2025-07-01)

A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD
by: Jheng-Yan Wu, et al.
Published: (2025-08-01)

Agregados tubulares em caso de atrofia espinhal cronica proximal
by: Lineu Cesar Werneck, et al.
Published: (1979-03-01)

The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure
by: Simone Pasquale Crispino, et al.
Published: (2025-03-01)

Loss of p300 in proximal tubular cells reduces renal fibrosis and endothelial-mesenchymal transition
by: Hyunsik Kim, et al.
Published: (2025-07-01)

SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)
by: Pasquale Paolisso, et al.
Published: (2024-11-01)

Long‐term efficacy of SGLT2 inhibitors for elderly patients with acute decompensated heart failure: The OASIS‐HF study
by: Michitaka Amioka, et al.
Published: (2025-02-01)

Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
by: Linda Piras, et al.
Published: (2024-11-01)

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
by: Mohamed Alhemeiri, et al.
Published: (2022-01-01)

A Review on the Relationship between SGLT2 Inhibitors and Cancer
by: Hao-Wen Lin, et al.
Published: (2014-01-01)

Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs
by: Divya Rajagopal, et al.
Published: (2024-10-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
by: Filip Rolski, et al.
Published: (2025-02-01)